Guideline development is one of the core activities of the European Society of Cardiology (ESC) as it seeks to promote evidence based care and reduce the burden of cardiovascular disease. In 2015, the ESC produced five new guidelines, one of which relates to the management of patients with ventricular arrhythmias and prevention of sudden cardiac death (SCD). 1 Nurses have participated in developing all of the five guidelines that were published in 2015. This development reflects a recognition within the ESC that chronic care of patients with cardiovascular conditions can be improved by involving all stakeholders, making use of multidisciplinary interventions, and placing the patient and the family at the centre of the care process. Patient-and family-centred care is grounded in mutually beneficial partnerships among healthcare providers, patients and families. Patient-centred care interventions focus on collaborative goal-setting between patients and healthcare professionals regarding immediate clinical choices and future care. This approach to care improves communication, collaborative decision-making, patient engagement and satisfaction. In implementing guidelines, routines need to be established to initiate, integrate and safeguard patient-centred care. 2,3 Within arrhythmia management and inherited cardiac conditions, nurses play a pivotal role in many aspects of delivering evidence-based care to patients and families. This means that nurses are key players in guideline development and implementation. The purpose of this paper, is to discuss the latest evidence and highlight some of the most pertinent issues for nurses involved in patient-centred care of patients and families with ventricular arrhythmias and/or risk of sudden death.
One of the novelties of this guideline is for the first time a focus on the psychosocial response of patients and family regarding screening, diagnosis and treatment. Indeed it is significant that 'Discussion of quality of life issues is recommended before implantable cardioverter defibrillator (ICD) implant and during disease progression in all patients' features in the top 10 recommendations of the guideline (Box 1). In addition, the guideline also acknowledges that there are gaps in evidence related to these issues, and highlights that 'more research is needed to establish evidence-based interventions to reduce psychosocial impact and optimise care and support for patients and families at risk of SCD' (Box 2).
Family members of sudden cardiac death survivors
Families of critically ill patients face an emotionally challenging situation with prognostic uncertainty, and are often required to take surrogate decisions. 4 Witnessing out-ofhospital-cardiac-arrest places a particular burden on family because they often initiate cardiopulmonary resuscitation of their loved one. 5 Families may worry about not having performed cardiopulmonary resuscitation correctly, and thus possibly causing their loved one to suffer brain damage or death. 6 Providing reassurance in order to reduce feelings of guilt is important. Adverse psychological outcomes in family members during critical illness are common. 7 The recovery phase after cardiac arrest remains challenging, 6 as patients and family may have different perspectives. 6 This may result in spousal overprotectiveness and other conflicts negatively influencing recovery, and highlights the need to improve family-centred care for sudden cardiac death survivors. Effective communication strategies that include the family appropriately, in decision-making regarding risk management and discharge planning, may prevent complications. 7 This entails establishing mutually beneficial partnerships among healthcare providers, patients, and families. For example, family members and patients with depressed left ventricular (LV) function which may resolve within weeks (e.g. myocarditis, post-myocardial infarction (MI), or after correction of severe mitral regurgitation) should be informed about the potential risk of SCD. Strategies such as a wearable defibrillator should be discussed with patients and family and their views taken 
General population
• • The analysis of blood and other adequately collected body fluids for toxicology and molecular pathology is recommended in all victims of unexplained sudden death. • • It is recommended that public access defibrillation is established at sites where cardiac arrest is relatively common and suitable storage is available (e.g. schools, sports stadiums, large stations, casinos, etc.) or in sites where no other access to defibrillation is available (e.g. trains, cruise ships, airplanes, etc.).
Patients with ICD indications
• • Discussion of quality-of-life issues is recommended before ICD implant and during disease progression in all patients.
Ischaemic heart disease
• • Re-evaluation of LVEF 6-12 weeks after myocardial infarction is recommended to assess the potential need for primary prevention ICD implantation. Patients with heart failure • • ICD therapy is recommended to reduce SCD in patients with symptomatic HF (NYHA class II or III) and LVEF ⩽35%, after ⩾3 months of optimal medical therapy, who are expected to survive at least one year with good functional status: -Ischaemic aetiology, and at least six weeks after myocardial infarction.
-Non-ischaemic aetiology.
• • CRT-D is recommended in patients with a QRS duration of ⩾130 ms, with an LVEF ⩽30%, and with a LBBB, despite at least three months of optimal pharmacological therapy, who are expected to survive at least one year with good functional status, to reduce all-cause mortality. • • CRT is recommended in patients with an LVEF ⩽35% and LBBB, despite at least three months of optimal pharmacological therapy, who are expected to survive at least one year with good functional status, to reduce all-cause mortality: -With a QRS duration of >150 ms.
-With a QRS duration of 120-150 ms.
Inherited arrhythmogenic diseases
• • Avoidance of competitive sports is recommended in patients with ARVC.
Emerging recommendations
• • Flecainide should be considered in addition to beta-blockers in patients with a diagnosis of CPVT who experience recurrent syncope or polymorphic/bidirectional VT while on beta-blockers, when there are risk/contra-indications for the ICD, or an ICD is not available or is rejected by the patient. account of in decision making. The new ESC guidelines states that a wearable defibrillator may be considered for adult patients with poor LV systolic function who are at risk of sudden arrhythmic death for a limited period, but are not candidates for an ICD. 1 Nurses will play an important role in the management and support of such patients.
Psychosocial impact of ICD treatment
Evidence regarding the psychosocial impact of ICD therapy is variable: Several early randomised controlled trials (RCTs) document similar or improved quality of life (QOL) in recipients compared to controls, 9, 10 while some patients report elevated anxiety (8-63%) and depression (5-41%) in the ICD group. 11 While the majority of patients and families with an ICD successfully adjust to therapy, inappropriate and/or frequent shocks can impair physical and psychological functioning. 12 The literature suggests that these problems frequently go unrecognised and untreated in clinical practice. 13 While immediate management should identify the cause of the device firing, treating psychological distress is also important. The frequency of appropriate shocks also has an impact and does seem to impair physical, emotional and psychological function. 9, 10 The levels of distress vary, Box 2. Gaps in evidence from the 2015 European Society of Cardiology (ESC) guideline (© The European Society of Cardiology and the European Respiratory Society 2015) on sudden cardiac death and ventricular arrhythmias. 1 The first clinical manifestation of sudden death is often lethal. Therefore, identification of patients at risk for sudden death remains the philosopher's stone of sudden death prevention. Risk stratification for primary prevention of SCD with invasive and noninvasive techniques is still unsatisfactory. Novel approaches including genetic profiling, ECG screening and imaging techniques need to be assessed. Research into the best methods to detect asymptomatic populations at risk for sudden death is urgently needed. Simple and cheap methods appropriate for mass screening are needed.
• • Ensuring an effective and rapid chain of care is of utmost importance to improve survival of sudden death victims. More research is needed to evaluate the optimal design of such survival chains including pre-hospital care and in-hospital protocols. • • The successes in preventing CAD and HF due to myocardial infarctions have substantially reduced sudden death rates. Further research into the other causes of sudden death is needed to further reduce sudden death rates. • • More than half of sudden death victims have a preserved LV function. Specific research programmes to understand the mechanisms causing sudden death in patients with preserved LV function is urgently needed, probably requiring interdisciplinary approaches including cardiologists, geneticists, epidemiologists, and basic and translational scientists. Such research should encompass better detection of patients with inherited cardiomyopathies and inherited arrhythmogenic disorders, sudden death risk stratification in patients with HF and preserved EF, and sudden death risk assessment in patients with AF. • • Wearable defibrillators may be an interesting therapeutic option in selected patients but require larger randomised trials before clear indications can be fully defined. • • Randomised trials on the feasibility of risk stratification with invasive electrophysiological study early after myocardial infarction are warranted. • • More than a decade has passed since the publication of landmark RCTs on primary prevention of SCD, which serve until present as the basis for ICD use in patients with LV systolic dysfunction and HF. Patient profile and medical treatment have changed significantly since: today's patients are older and have more co-morbidities such as AF, chronic kidney disease, and others. Thus, new clinical trials are needed to assess the potential benefit of primary prevention of SCD with an ICD for today's patient population. As no relevant new RCTs are underway, data from prospective registries might shed more light on this clinically very important issue. • • More research is needed to establish evidence-based interventions to reduce psychosocial impact and optimise care and support for patients and families at risk of SCD. • • Many patients with reduced ejection fraction will experience an improvement in LVEF over time. Some of these patients will receive a defibrillator without a clear need, while others may remain at risk for sudden death despite recovery of LV function. More research into the best assessment of these patients is needed to allow a better, personalised sudden death management. • • The use of CRT(-D) in patients with AF, and the place of AV nodal ablation, has not been well defined outside of observational datasets. There is a clear need for adequately powered randomised trials in this common patient group. • • The field of inherited arrhythmias and cardiomyopathies has faced major advances in the last 20 years, mainly due to the widespread availability of genetic diagnosis and to the availability of clinical data from large registries. However, key gaps in evidence still exist. A large number of patients with primary inherited arrhythmias and cardiomyopathies still die before a diagnosis is made, thus suggesting the need for improved diagnostic approaches. Knowledge gaps also exist in risk-stratification schemes for diseases such as Brugada syndrome, SQTS ARVC, and most of the non-ischaemic dilated cardiomyopathies. • • VTs worsen the prognosis of patients with a variety of structural heart diseases. New anti-arrhythmic or other medical therapy is urgently needed to allow a broader population to be protected from first or recurrent life-threatening VAs. It remains to be tested whether specific anti-arrhythmic treatment can improve that prognosis. While catheter ablation of recurrent VT in patients with structural heart disease has been shown to significantly reduce the number of VT recurrences, the impact of VT catheter ablation on mortality is unclear and warrants investigation. but patients can present with more severe forms, such as post-traumatic stress disorder (PTSD), 14 and both shock history and pre-implantation distress are predictors of PTSD symptoms. 15 ICD patients with recent tachyarrhythmia can also display anticipatory shock anxiety. 16 Patients with high levels of pre-implantation ICD-related concerns have shown to have a poorer prognosis, independent of other risk markers, 17 and depression may have negative impact on prognosis and QOL in this population. 18 In follow-up of patients, analysis of concerns and psychological status, including anxiety and depression, is an important consideration. Interventions to reduce psychological distress may include device-related education, stress management, cognitive behaviour therapy, social support and exercise programmes. 19, 20 Importantly, the negative effects of inappropriate shocks may be similar to those of adequate shocks from the patients' perspective. Treatment to avoid future shocks can provide reassurance to patients, but psychological support seems helpful too. Thus, the new ESC guideline states assessment of psychological status and treatment of distress in patients with recurrent inappropriate shocks as a Class I recommendation. 1 Arrhythmias can affect many areas in the life of patients and family, like ability to drive, 21 intimate relations, 22 sleep quality, 23 body image concerns (particularly in younger women), 24 and participation in organised sports (particularly in children and adolescents). 25 Some of these areas are affected by ICD therapy as well. In order to maximise the derived benefit of the ICD, these issues need to be addressed in the care and counselling of patients. Importantly, the ICD-related information needs to be tailored to the needs of the patient taking age, sex and comorbidities into consideration. Reinforcement of the information provided before implant is pivotal, but needs to consider the potentially dynamic illness trajectory of ICD patients. In pre-implant education, positive communication strategies can emphasise the protective value of the ICD versus risk of SCD. 19 The ESC guideline recommends discussion of QOL issues before ICD implantation and during disease progression as a Class I recommendation in all patients. 1
Preventing SCD in the elderly
The general consensus is that age does not impact on clinical decisions made concerning patients with arrhythmias or at risk of SCD. However, consideration of comorbidities, drug interactions, altered drug elimination, and side effects, life expectancy, procedural risks and patient preferences are of particular concern in this subgroup. 1 When prescribing antiarrhythmic drugs to elderly patients, decreased renal and hepatic clearance, changes in body composition and presence of comorbidities must be considered. Older patients are commonly on multiple drugs for comorbid conditions, increasing the risk of drug interactions and therefore dose adjustment may be warranted. Beta blockers are considered the mainstay of antiarrhythmic drug therapy after acute MI, but underused in the elderly, although shown to reduce SCD in patients >65 years of age. 26 The guideline states therefore that beta blockers should be considered in older patients without specific contraindications.
While ICDs are often used in the elderly, no RCT has specifically investigated their role in this population. Subgroup analysis in both Antiarrhythmics versus Implantable Defibrillators (AVID) and Multicenter Automatic Defibrillator Implantation Trial (MADIT II) trials demonstrated equivalent benefits from ICD in older and younger patients. 27, 28 Meta-analyses however, show divergent results. [29] [30] [31] Observational studies and registry data from real-world clinical settings in primary prevention patients demonstrate that age alone should not preclude device implantation. 32, 33 A comparison between patients from a large registry who were older and had more comorbidities showed a similar survival rate as that of patients in the two largest primary prevention clinical trials, MADIT-II and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 34 Equally important are the implications for QOL as this is often a critical factor in clinical decision making in this subpopulation. Data relating to QOL and age however, are sparse. QOL in terms of quality-adjusted life years (QALYs) is also of concern. In a MADIT-II sub-study, no significant decrease in QALYs for patients ⩾65 years was established. 35 Older patients are a heterogeneous group, and octogenarians who die suddenly can be highly functional even in the month before their death. 36 Still, selected very old patients with multiple comorbidities and limited life expectancy may not be appropriate candidates even if meeting standard criteria for the ICD. The new ESC guideline states that clinical judgment coupled with the wishes of the patient and/or family may, in some case, take precedence over standard guideline recommendations on the use of ICDs. 1
End-of-life issues
It has been found that ICDs are rarely deactivated 37 and around 30% of patients with ICDs receive shocks in the last 24 hours of their lives. 38 Terminally ill patients are more likely to develop hypoxia, pain, heart failure and electrolyte disturbances predisposing them to arrhythmias and thus increasing the frequency of shock therapy from ICDs. 39 Shocks can be physically painful and psychologically stressful. In patients at the end of life this creates an unnecessary burden to the dying patient and family, 40 and thus is inconsistent with palliative care goals. 41 Deactivation of an ICD in a patient who is dying of a terminal illness, whether cardiac or another condition, prevents the delivery of painful ICD shocks. 42 Individual consideration should be given based on the four ethical principles in medicine; respect for patient autonomy, beneficence, non-maleficence and justice. 43 Honouring both informed consent and informed refusal is an integral part of these principles. Cognitively competent patients who wish to have the ICD deactivated to prevent further suffering are entitled to have this performed. When patients lose capacity, an advance directive or next of kin should be consulted. In cases where the clinician refrains from deactivation due to personal beliefs, a second physician willing to carry out the procedure should be involved. 39, 44 The ESC guideline recommends discussion of end-oflife issues with all patients before implantation and at significant points along the illness trajectory. 1 Discussing deactivation with the patient and family at the end of life is imperative in order to prevent undue burden on dying patients. Studies suggest that physicians are willing to discuss ICD deactivation at end of life, but rarely do so, 44, 45 resulting in most devices remaining active until death. However, patients and family welcome end-of-life discussions concerning ICDs 46 which confirms an opportunity for nurses to more effectively contribute to patient-centred care in this arena. A recent study showed that insufficient knowledge in ICD patients was associated with indecisiveness about ICD deactivation, potentially resulting in a distressing end-of-life situation. 47 A discussion of this option prior to implant should be considered. A validated questionnaire may be helpful to initiate such discussions. 48 The patient should also be informed that after device deactivation the patient can reconsider this decision and choose to re-activate all device functions. The results of the discussion should be noted in medical records following certain requirements. 44 A multidisciplinary team effort (physicians, nurses, allied health professionals) is important in order to guide the patient through the decision and following procedure. Before, during and after deactivation, patients should not be left alone, and family support should be encouraged. Deactivation is a procedure achieved by device re-programming, or application of a magnet directly over the device. It may be preferable to suspend only shock and anti-tachycardia therapies and maintain pacing for bradycardia to avoid symptomatic deterioration. A pacemaker as opposed to an ICD will not resuscitate a patient, but can prevent symptomatic bradycardia and worsening of heart failure, and thus improve quality of life of the patient. 39, 49 For patients who are unable to travel, the physician in charge should arrange for a programmer to be brought to the patient, whether that be in a nursing home, hospice or their own home. 44 The ESC guideline recommends that ICD deactivation should be considered when the patients' clinical condition deteriorates. 1 However, care of patients does not end with device deactivation, and nurses will often play an important role in the palliative care interventions to minimise symptoms that need to be implemented. 49
Conclusion
Nurses and allied professionals are at the forefront of care delivery in patients with arrythmogenic risk and have a responsibility to deliver care that is focused on individual needs. The 2015 ESC guidelines herald a step-change in patient and family focus and interdisciplinary involvement. The ESC Council on Cardiovascular Nursing and Allied Professionals has launched a Be Guideline Smart Initiative. The Toolkit developed as part of this initiative offers a range of online resources available at: http://www. escardio.org/Councils/Council-on-Cardiovascular-Nursing-and-Allied-Professions-(CCNAP)/be-guidelinessmart. The role of nurses in actually implementing the guideline recommendations in everyday clinical practice throughout Europe needs to be optimised. As you update on the latest news in the prevention of ventricular arrhythmias and SCD, we encourage you to take a look at this toolkit and consider if it may be useful to you in implementing these recommendations.
Implications for practice
• • Nurses and allied professionals are at the forefront of care delivery in patients with arrythmogenic risk and have a responsibility to deliver care that is patient and family-centred. • • The 2015 guideline heralds a step-change in patient and family focus and interdisciplinary involvement in that it advocates:
| |
An interdisciplinary approach to patient education and counselling by the clinical team pre-implant, in follow-up and rehabilitation, and at end of life is at the core of care.
Treatment strategies should be discussed with patients and family and their views taken account of in decision making.
In order to maximise the derived benefit of the implantable cardioverter defibrillator (ICD), a holistic perspective that includes quality of life issues should be pivotal in the care and counselling of patients.
Information should be tailored to the needs of the patient taking age, sex, and comorbidities into consideration. Reinforcement of the information provided before implant is pivotal, but needs to consider the potentially dynamic illness trajectory of ICD patients.
Discussing deactivation with the patient and family from the pre-implantation stage and at periods of deterioration is imperative in order to prevent undue burden on dying patients.
• • The European Society of Cardiology (ESC) Council
on Cardiovascular Nursing and Allied Professionals has launched a Be Guideline Smart Initiative. The Toolkit developed as part of this initiative offers a range of online resources that can assist in implementing guideline recommendations.
